公开(公告)号：US20220348570A1

公开(公告)日：2022-11-03

申请号：US17183401

申请日：2021-02-24

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Jean-Christophe Andrez ,  Kristen Nicole Burford ,  Christoph Martin Dehnhardt ,  Thilo Focken ,  Michael Edward Grimwood ,  Qi Jia ,  Verner Alexander Lofstrand ,  Shaoyi Sun ,  Steven Sigmund Wesolowski ,  Michael Scott Wilson ,  Alla Yurevna Zenova

IPC: C07D417/14 ,  C07D401/12 ,  C07D401/14 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D487/08

Abstract: This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.

公开(公告)号：US20240101531A1

公开(公告)日：2024-03-28

申请号：US18330100

申请日：2023-06-06

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Paul Scott Charifson ,  Christoph Martin Dehnhardt ,  Julien A. Delbrouck ,  Thilo Focken ,  Wei Gong ,  Shawn Johnstone ,  Xiangyu Li ,  Jia Yi Mo ,  Juliette Sabbatani ,  Hong Wang ,  Steven Sigmund Wesolowski ,  Alla Yurevna Zenova ,  Wei Zhang

IPC: C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D495/04 ,  C07D513/04 ,  C07D471/04 ,  C07D491/048 ,  C07D491/107 ,  C07D498/04 ,  C07D413/14 ,  C07D487/04 ,  C07D417/14 ,  C07D409/14 ,  C07B59/00 ,  A61P25/08

CPC classification number: C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D495/04 ,  C07D513/04 ,  C07D471/04 ,  C07D491/048 ,  C07D491/107 ,  C07D498/04 ,  C07D413/14 ,  C07D487/04 ,  C07D417/14 ,  C07D409/14 ,  C07B59/002 ,  A61P25/08 ,  C07B2200/05

Abstract: The present disclosure is directed to compounds of Formula (1):




wherein m, n, Y, R1, R2, R3, R4 and R5 are each as described herein, as stereoisomers, enantiomers or tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, and pharmaceutical compositions comprising the compounds of Formula (I), as described herein, which are useful as voltage-gated potassium channel modulators and are therefore are useful in treating seizure disorders such as epilepsy.

公开(公告)号：US10981905B2

公开(公告)日：2021-04-20

申请号：US16556055

申请日：2019-08-29

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Jean-Christophe Andrez ,  Kristen Nicole Burford ,  Christoph Martin Dehnhardt ,  Thilo Focken ,  Michael Edward Grimwood ,  Qi Jia ,  Verner Alexander Lofstrand ,  Shaoyi Sun ,  Steven Sigmund Wesolowski ,  Michael Scott Wilson ,  Alla Yurevna Zenova

IPC: C07D471/04 ,  A61K31/437 ,  C07D417/14 ,  C07D401/12 ,  C07D401/14 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D487/08

Abstract: This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.

公开(公告)号：US20200157089A1

公开(公告)日：2020-05-21

申请号：US16556055

申请日：2019-08-29

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Jean-Christophe Andrez ,  Kristen Nicole Burford ,  Christoph Martin Dehnhardt ,  Thilo Focken ,  Michael Edward Grimwood ,  Qi Jia ,  Verner Alexander Lofstrand ,  Shaoyi Sun ,  Steven Sigmund Wesolowski ,  Michael Scott Wilson ,  Alla Yurevna Zenova

IPC: C07D417/14 ,  C07D417/12 ,  C07D401/14 ,  C07D401/12 ,  C07D409/12 ,  C07D487/08 ,  C07D471/04 ,  C07D413/12

Abstract: This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.

公开(公告)号：US20200071313A1

公开(公告)日：2020-03-05

申请号：US16555983

申请日：2019-08-29

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Jean-Christophe Andrez ,  Kristen Nicole Burford ,  Christoph Martin Dehnhardt ,  Thilo Focken ,  Michael Edward Grimwood ,  Qi Jia ,  Verner Alexander Lofstrand ,  Steven Sigmund Wesolowski ,  Michael Scott Wilson

IPC: C07D417/14 ,  C07D409/14 ,  C07D401/14 ,  A61P25/08 ,  C07C53/18

Abstract: This invention is directed to heteroaryl-substituted sulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.

公开(公告)号：US11639351B2

公开(公告)日：2023-05-02

申请号：US17183401

申请日：2021-02-24

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Jean-Christophe Andrez ,  Kristen Nicole Burford ,  Christoph Martin Dehnhardt ,  Thilo Focken ,  Michael Edward Grimwood ,  Qi Jia ,  Verner Alexander Lofstrand ,  Shaoyi Sun ,  Steven Sigmund Wesolowski ,  Michael Scott Wilson ,  Alla Yurevna Zenova

IPC: A61K31/4436 ,  A61K31/444 ,  C07D417/14 ,  C07D401/12 ,  C07D401/14 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D487/08

Abstract: This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.

公开(公告)号：US10752623B2

公开(公告)日：2020-08-25

申请号：US16555983

申请日：2019-08-29

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Jean-Christophe Andrez ,  Kristen Nicole Burford ,  Christoph Martin Dehnhardt ,  Thilo Focken ,  Michael Edward Grimwood ,  Qi Jia ,  Verner Alexander Lofstrand ,  Steven Sigmund Wesolowski ,  Michael Scott Wilson

IPC: C07D417/14 ,  A61P25/08 ,  C07C53/18 ,  C07D401/14 ,  C07D409/14

Abstract: This invention is directed to heteroaryl-substituted sulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.